Indiana University Simon Cancer Center

Site:	Indiana University Simon Cancer Center	Go to their website
Address:	535 Barnhill Drive
City:	Indianapolis
State:	IN
Zip:	46202
Country:	USA

Phase	Trial [asc]	Trial Status	Site Status	Drug	NCT#
1	A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PI Kinase (PI3K) Inhibitor, Given Twice Weekly by IV Infusion to Patients With Advanced or Metastatic Tumors	Ongoing, but not recruiting	Closed	SF1126	NCT00907205
2	A Phase II Study of IMC-A12 in Children With Relapsed/Refractory Solid Tumors	Does not allow GIST	Active	IMC-A12	NCT00831844
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
1	Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma and Gastrointestinal Stromal Tumors (TH-CR-410)	Unknown	Closed	Sunitinib + TH-302	NCT01381822
2	Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	Completed	Closed	Dovitinib	NCT01831726
3	Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients	Terminated	Closed	Imatinib	NCT01031628
3	Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib	Terminated	Closed	IPI-504	NCT00688766
2	Trial of Dasatinib in Advanced Sarcomas	Ongoing, but not recruiting	Closed	Dasatinib (BMS-354825)	NCT00464620